Mersana Therapeutics to Participate in Investor Conferences in September
August 31 2017 - 7:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN) today announced that Anna
Protopapas, President and Chief Executive Officer, will participate
in three upcoming investor conferences in September. Details are as
follows:
Baird 2017 Global Healthcare
ConferenceDate/time:
Wednesday, September 6th at 3:10 p.m. E.T.Location:
New York, NY
Cantor Fitzgerald Global Healthcare
ConferenceDate/time:
Wednesday, September 27th at 3:25 p.m. E.T.Location:
New York, NY
Leerink Partners Roundtable Series: Rare Disease &
Immuno-OncologyDate/time:
Thursday, September 28th at 8:00 a.m. E.T.Location:
New York, NY
Live webcasts of the presentations will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. Archived replays will be available for
approximately 60 days following the presentations.
About Mersana
Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company
using its differentiated and proprietary ADC platforms to develop
highly targeted drugs with increased tolerability and expanded
opportunities to deliver meaningful clinical benefit to
patients. Mersana’s lead product candidate, XMT-1522, is in
Phase I clinical trials in patients with advanced tumors expressing
HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC)
and gastric cancer patients. The Company expects that its second
product candidate, XMT-1536, will enter clinical trials in early
2018. In addition, multiple partners are using Mersana’s leading
platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
paulkidwell@comcast.net
617-680-1088
Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
Christina@sternir.com
(212) 362-1200
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024